Nuclera
Drug discovery requires custom protein reagents, which are time-consuming and costly to produce. Revolutionising the way proteins are made, Nuclera’s benchtop eProtein Discovery™ platform provides faster and easier access to scalable, soluble and active proteins in under 48 hours by combining unique cell-free technologies and novel digital microfluidics, which speeds up drug discovery processes by up to 30x.
In Q2 2024, Nuclera announced it had, to date, installed its platform at 11 world-leading academic institutions, including the University of Cambridge, Massachusetts Institute of Technology (MIT) and University College London (UCL), with further installations scheduled.
Nuclera recently closed a $75m Series C led by American backer Elevage Medical Technologies and started stepping up commercialisation, notably across the US and Europe. The company's headquarters are in Cambridge, with a second base in Boston, Massachusetts.
